ORLANDO—Intermittent and continuous androgen suppression are associated with similar overall survival outcomes in men who have PSA progression after radiotherapy for prostate cancer (PCa), according to new data.
The data were derived from a pivotal study of 1,386 men who underwent radiotherapy for PCa and experienced a rising PSA. Researchers led by Laurence Klotz, MD, of Sunnybrook Health Sciences Centre in Toronto, randomized 690 subjects to receive intermittent androgen suppression (IAS) and 696 to receive continuous androgen deprivation (CAD). After a median follow-up of 6.9 years, the median overall survival in the IAS and CAD arms was 8.8 and 9.1 years, respectively, a nonsignificant difference between the groups, Dr. Klotz told attendees of the fourth annual Genitourinary Cancers Symposium.
Subjects in the IAS arm had a 20% decreased likelihood of developing hormone refractory disease compared with the CAD group. The IAS group had a reduced incidence of hot flashes but otherwise the two study arms had similar adverse event profiles, the study showed.
Intermittent androgen suppression should be the standard of care for most patients with PSA recurrence after radiotherapy initiating androgen deprivation therapy, with or without prior radical prostatectomy, Dr. Klotz said.